Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Different Selected Mechanisms Attenuated the Inhibitory Interaction of KIR2DL1 with C2+ HLA-C in Two Indigenous Human Populations in Southern Africa.

Nemat-Gorgani N, Hilton HG, Henn BM, Lin M, Gignoux CR, Myrick JW, Werely CJ, Granka JM, Möller M, Hoal EG, Yawata M, Yawata N, Boelen L, Asquith B, Parham P, Norman PJ.

J Immunol. 2018 Apr 15;200(8):2640-2655. doi: 10.4049/jimmunol.1701780. Epub 2018 Mar 16.

2.

An Unexpectedly Complex Architecture for Skin Pigmentation in Africans.

Martin AR, Lin M, Granka JM, Myrick JW, Liu X, Sockell A, Atkinson EG, Werely CJ, Möller M, Sandhu MS, Kingsley DM, Hoal EG, Liu X, Daly MJ, Feldman MW, Gignoux CR, Bustamante CD, Henn BM.

Cell. 2017 Nov 30;171(6):1340-1353.e14. doi: 10.1016/j.cell.2017.11.015.

3.

Structural and functional effects of nucleotide variation on the human TB drug metabolizing enzyme arylamine N-acetyltransferase 1.

Cloete R, Akurugu WA, Werely CJ, van Helden PD, Christoffels A.

J Mol Graph Model. 2017 Aug;75:330-339. doi: 10.1016/j.jmgm.2017.04.026. Epub 2017 Jun 10.

4.

N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.

Sy SK, de Kock L, Diacon AH, Werely CJ, Xia H, Rosenkranz B, van der Merwe L, Donald PR.

Antimicrob Agents Chemother. 2015 Jul;59(7):4129-38. doi: 10.1128/AAC.04049-14. Epub 2015 May 11.

5.

Acquired drug resistance during inadequate therapy in a young child with tuberculosis.

Garcia-Prats AJ, Willemse M, Seifart HI, Jordaan AM, Werely CJ, Donald PR, Schaaf HS.

Pediatr Infect Dis J. 2014 Aug;33(8):883-5. doi: 10.1097/INF.0000000000000336.

PMID:
25222312
6.

Pharmacokinetics of isoniazid in low-birth-weight and premature infants.

Bekker A, Schaaf HS, Seifart HI, Draper HR, Werely CJ, Cotton MF, Hesseling AC.

Antimicrob Agents Chemother. 2014;58(4):2229-34. doi: 10.1128/AAC.01532-13. Epub 2014 Feb 3.

7.

Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants.

Kiser JJ, Zhu R, DʼArgenio DZ, Cotton MF, Bobat R, McSherry GD, Madhi SA, Carey VJ, Seifart HI, Werely CJ, Fletcher CV.

Ther Drug Monit. 2012 Aug;34(4):446-51. doi: 10.1097/FTD.0b013e31825c4bc3.

8.

Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Thee S, Seddon JA, Donald PR, Seifart HI, Werely CJ, Hesseling AC, Rosenkranz B, Roll S, Magdorf K, Schaaf HS.

Antimicrob Agents Chemother. 2011 Dec;55(12):5560-7. doi: 10.1128/AAC.05429-11. Epub 2011 Oct 3.

9.

The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid.

Zhu R, Kiser JJ, Seifart HI, Werely CJ, Mitchell CD, D'Argenio DZ, Fletcher CV.

J Clin Pharmacol. 2012 Apr;52(4):511-9. doi: 10.1177/0091270011402826. Epub 2011 May 10.

10.

Pyridoxal-5-phosphate plasma concentrations in children receiving tuberculosis chemotherapy including isoniazid.

Cilliers K, Labadarios D, Schaaf HS, Willemse M, Maritz JS, Werely CJ, Hussey G, Donald PR.

Acta Paediatr. 2010 May;99(5):705-710. doi: 10.1111/j.1651-2227.2010.01696.x. Epub 2010 Feb 8.

PMID:
20146723
11.

Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.

McIlleron H, Willemse M, Werely CJ, Hussey GD, Schaaf HS, Smith PJ, Donald PR.

Clin Infect Dis. 2009 Jun 1;48(11):1547-53. doi: 10.1086/598192.

PMID:
19392636
12.

The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.

Donald PR, Parkin DP, Seifart HI, Schaaf HS, van Helden PD, Werely CJ, Sirgel FA, Venter A, Maritz JS.

Eur J Clin Pharmacol. 2007 Jul;63(7):633-9. Epub 2007 May 16.

PMID:
17505821
13.

NAT2 polymorphisms and their influence on the pharmacology and toxicity of isoniazid in TB patients.

Werely CJ, Donald PR, van Helden PD.

Per Med. 2007 May;4(2):123-131. doi: 10.2217/17410541.4.2.123.

PMID:
29788627
14.

Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.

Schaaf HS, Parkin DP, Seifart HI, Werely CJ, Hesseling PB, van Helden PD, Maritz JS, Donald PR.

Arch Dis Child. 2005 Jun;90(6):614-8.

15.
16.

NAT2 slow acetylator function as a risk indicator for age-related cataract formation.

Meyer D, Parkin DP, Seifart HI, Maritz JS, Engelbrecht AH, Werely CJ, van Helden PD.

Pharmacogenetics. 2003 May;13(5):285-9.

PMID:
12724621
17.

DNA fingerprint detection of somatic mutations in benign prostatic hyperplasia and prostatic adenocarcinoma.

Werely CJ, Heyns CF, Van Velden DJ, Van Helden PD.

Genes Chromosomes Cancer. 1996 Sep;17(1):31-6.

PMID:
8889504
18.

The glycosaminoglycans of the gubernaculum during testicular descent in the fetus.

Heyns CF, Human HJ, Werely CJ, De Klerk DP.

J Urol. 1990 Mar;143(3):612-7.

PMID:
2106043
19.

Supplemental Content

Loading ...
Support Center